학술논문
Risk of thyroid as a first or second primary cancer. A population‐based study in Italy, 1998–2012
Document Type
article
Author
Emanuele Crocetti; Veronica Mattioli; Carlotta Buzzoni; Silvia Franceschi; Diego Serraino; Salvatore Vaccarella; Stefano Ferretti; Susanna Busco; Ugo Fedeli; Massimo Varvarà; Fabio Falcini; Manuel Zorzi; Giuliano Carrozzi; Walter Mazzucco; Cinzia Gasparotti; Silvia Iacovacci; Federica Toffolutti; Rossella Cavallo; Fabrizio Stracci; Antonio G. Russo; Adele Caldarella; Stefano Rosso; Antonino Musolino; Lucia Mangone; Claudia Casella; Mario Fusco; Giovanna Tagliabue; Daniela Piras; Rosario Tumino; Linda Guarda; Ylenia M. Dinaro; Silvano Piffer; Pasquala Pinna; Guido Mazzoleni; Anna C. Fanetti; Luigino Dal Maso; for AIRTUM working group
Source
Cancer Medicine, Vol 10, Iss 19, Pp 6855-6867 (2021)
Subject
Language
English
ISSN
2045-7634
Abstract
Abstract Background The number of patients living after a cancer diagnosis is increasing, especially after thyroid cancer (TC). This study aims at evaluating both the risk of a second primary cancer (SPC) in TC patients and the risk of TC as a SPC. Methods We analyzed two population‐based cohorts of individuals with TC or other neoplasms diagnosed between 1998 and 2012, in 28 Italian areas covered by population‐based cancer registries. Standardized incidence ratios (SIRs) of SPC were stratified by sex, age, and time since first cancer. Results A total of 38,535 TC patients and 1,329,624 patients with other primary cancers were included. The overall SIR was 1.16 (95% CI: 1.12–1.21) for SPC in TC patients, though no increase was shown for people with follicular (1.06) and medullary (0.95) TC. SPC with significantly increased SIRs was bone/soft tissue (2.0), breast (1.2), prostate (1.4), kidney (2.2), and hemolymphopoietic (1.4) cancers. The overall SIR for TC as a SPC was 1.49 (95% CI: 1.42–1.55), similar for all TC subtypes, and it was significantly increased for people diagnosed with head and neck (2.1), colon–rectum (1.4), lung (1.8), melanoma (2.0), bone/soft tissue (2.8), breast (1.3), corpus uteri (1.4), prostate (1.5), kidney (3.2), central nervous system (2.3), and hemolymphopoietic (1.8) cancers. Conclusions The increased risk of TC after many other neoplasms and of few SPC after TC questions the best way to follow‐up cancer patients, avoiding overdiagnosis and overtreatment for TC and, possibly, for other malignancies.